Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21126648 | 0.88 | CYP2C9 (0.40) | CYP2C9CYP2C19TDP1 | |
| SCHEMBL12790496 | 0.79 | MEN1 (0.39) | CYP2C9CYP2C19 | |
| SCHEMBL25553529 | 0.77 | CYP2C19 (0.60) | CYP2C9CYP2C19TDP1MAPT | |
| SCHEMBL15467596 | 0.76 | CYP2C19 (0.38) | CYP2C9CYP2C19 | |
| SCHEMBL22952336 | 0.76 | CYP2C9 (0.32) | CYP2C9CYP2C19 | |
| SCHEMBL13216010 | 0.76 | TSHR (0.44) | CYP2C9CYP2C19TDP1 | |
| SCHEMBL863534 | 0.75 | — | — | |
| SCHEMBL188592 | 0.75 | — | — | |
| SCHEMBL19544283 | 0.74 | CYP2C9 (0.30) | CYP2C9CYP2C19 | |
| SCHEMBL13356289 | 0.74 | ANPEP (0.33) | CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110052673-A1 | THERAPEUTIC COMPOSITIONS | SHIRE HUMAN GENETIC THERAPIES, INC. | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052673-A1 | THERAPEUTIC COMPOSITIONS | PHOSPHO1, SGMS1, APOB | CYP2C9 3954/4885CYP2C19 3965/4885TDP1 3041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.